Nuclear Medicine
Browse by
Recent Submissions
-
Development of a 223radium dichloride (Xofigo) patient pathway for metastatic castrate-resistant prostate cancer (mCRPC) that prresent to the The Royal Wolverhampton NHS Trust following an alert by the Medicines and Healthcare Products Regulatory Agency (6th August 2018).
(The Royal Wolverhampton NHS Trust, 2018-10-10)Nobody knows the exact number in the UK, but approximately 90% of the prostate cancer deaths per year in this country are from cancer that has metastasized to bone. There are various possible sequences of therapy available ... -
A follow up dose-rate measurement strategy for patients post 131Iodine ablation therapy: can we improve the post treatment restrictions applied to the patient on discharge?
(The Royal Wolverhampton NHS Trust., 2018-10-10)131Iodine Ablation Therapy is used in the treatment of some thyroid cancers, specifically papillary and follicular thyroid cancer. The patients are referred post thyroidectomy, for post-operative radioactive iodine ablation ... -
Iodine restricting diet prior to radioiodine therapy (RAI) for hyperthyroidism - does it help?
(The Royal Wolverhampton NHS Trust., 2018-09)Background: There has been conflicting evidence on the use of strict dietary iodine restriction prior to Radioiodine (RAI) administration for the management of hyperthyroidism and varying level of restrictions have been ... -
Investigation into the contamination hazard associated with technegas administration.
(The Royal Wolverhampton NHS Trust., 2018-04-14)The breakdown of a pre-existing fume extraction system led to a review of safety provisions surrounding the administration of Technegas. Previous literature has identified a hazard from airborne radioactive contamination. ... -
Radiochemical purity testing of hepatobiliary iminodiacetic acid (HIDA).
(The Royal Wolverhampton NHS Trust., 2018-10-10)The results suggest that the most important part of the RCP process is to make sure the sample spot is dry before placing it in to the solvent. The time between the kit being manufactured and the RCP sample being taken did ... -
Bio distribution mapping of 223radium dichloride during the course of treatments 2 to 6: a patient case study.
(The Royal Wolverhampton NHS Trust., 2018-10-10)Prostate cancer is diagnosed in over 47,000 men per year in the UK and caused 11,631 deaths in 2016 (1). 90% of men with the disease have bone metastases (2) , and in 80% these cause debilitating pain or other symptoms. ... -
Rationalise radium: reducing delays between treatment cycles of 223radium dichloride
(The Royal Wolverhampton NHS Trust, 2020-10-21)223Radium dichloride is a radiopharmaceutical which irreversibly affects tumour cell DNA to cause necrosis, specifically targeting bone lesions. It is therefore used in patients with bone disease without other metastatic ...
RSS 1.0